Stories Tagged as
Allergan
Botox is a multi-billion dollar, potentially deadly monopoly
by
Kai Ryssdal
, Emily Henderson
and Sean McHenry
Oct 31, 2017
The product comes from a substance so lethal that it could be used as a potential agent of bioterrorism.
Pharma: an industry shaped by shareholder value
by
Dan Bobkoff
Jun 15, 2016
Big drug companies today have remade their business models.
The only way to stop inversions might be tax reform
Apr 6, 2016
The Pfizer-Allergan merger is out, but what about inversions across the board?
Pfizer abandons $160B Allergan deal
Apr 6, 2016
A change in U.S. tax laws has put a halt to the merger.
Pfizer's tax-driven Allergan merger
Nov 23, 2015
Regulators want to cut down on these deals, but this one is full-speed ahead.
Pfizer and Allergan agree to $160 billion "inversion"
Nov 23, 2015
The deal would create the largest pharmaceutical company in the world.
Activist investors help shareholders, right?
Apr 22, 2014
A new study says activist investors generated 48 percent average gain for companies they targeted.
For public good, not for profit.
Botox might help migraines
by
Lori Stassi
Sep 12, 2008
Botox eases wrinkles, but can it also ease migraine headaches? Allergan says it can. The company that produces Botox reports that two large tests...